Axonal loss is the destruction or degeneration of axons, the long cable-like extensions of nerve cells that carry electrical signals throughout the body. It is a feature of dozens of neurological conditions, from multiple sclerosis and ALS to diabetic neuropathy and traumatic brain injury, and the symptoms it produces depend almost entirely on which axons are affected and how many are lost. Because axons in the brain and spinal cord regenerate poorly compared with those in the rest of the body, the consequences of central axonal loss tend to be permanent, which is why so much research now focuses on catching it early and slowing it down rather than trying to reverse it after the fact.
What Keeps Axons Alive and What Triggers Their Destruction
An axon’s survival depends on a constant tug-of-war between molecules that maintain it and molecules that are primed to tear it apart. On the protective side sit survival factors, including the enzymes NMNAT2 and STMN2, which keep the axon’s internal environment stable. On the destructive side sit molecules like SARM1 and DLK, which can initiate a self-destruct sequence when the balance tips against the axon.1PubMed Central. The SARM1 axon degeneration pathway: control of the NAD+ metabolome regulates axon survival in health and disease Under normal conditions NMNAT2 is constantly shuttled down the axon from the cell body, replenishing the supply of NAD+, a molecule axons need for energy. If that supply is interrupted, whether by injury, disease, or a transport blockage, SARM1 activates and rapidly destroys the remaining NAD+, effectively starving the axon from the inside. The result is fragmentation: the axon breaks apart into debris.
Mitochondria, the tiny power plants inside axons, also play an early role. In conditions ranging from multiple sclerosis to age-related neurodegeneration, mitochondrial dysfunction shows up before axons visibly break down. Problems include oxidative stress, energy shortages, and breakdowns in the transport system that moves mitochondria to where they are needed along the axon’s length.2PubMed Central. Mitochondrial Behavior in Axon Degeneration and Regeneration In multiple sclerosis specifically, researchers have documented deficiencies in the mitochondrial respiratory chain that reduce a neuron’s ability to make ATP. This energy shortfall is compounded by the fact that demyelinated axons need more energy than usual to transmit signals, creating a mismatch between supply and demand that is especially damaging in the long nerve tracts running through the spinal cord.3PubMed. Mitochondrial dysfunction and axon degeneration in progressive multiple sclerosis
Wallerian Degeneration and How Injured Nerves Clear Themselves
When a peripheral nerve is physically cut or crushed, everything downstream from the injury undergoes a process called Wallerian degeneration. First described in 1850 by Augustus Waller, who severed frog nerves and watched the downstream portions fall apart over the following days, this process is now understood to be a tightly regulated self-destruct program rather than a passive decay.4PubMed Central. Wallerian degeneration: From mechanism to disease to imaging The degeneration unfolds in phases: an early phase in which the axon begins to lose structural integrity, followed by an execution phase during which the axon and its surrounding myelin sheath fragment into small pieces.5PubMed Central. Wallerian Degeneration and Nerve Regeneration-A Review of Cellular and Molecular Events
Counterintuitively, this destruction is necessary for recovery. The immune system’s innate-immune cells move in to clear the debris, removing the remnants of myelin that would otherwise block regrowing axons. At the same time, the cleared tissue ramps up production of growth-supporting signals, converting the damaged zone into an environment that actually encourages new axonal sprouts to extend back toward their original targets.6PubMed Central. Wallerian degeneration: the innate-immune response to traumatic nerve injury This cleanup-and-rebuild sequence works reasonably well in peripheral nerves. In the brain and spinal cord, by contrast, the glial cells responsible for the environment respond very differently to injury, and that distinction has enormous consequences for who recovers and who does not.
Major Causes of Axonal Loss
Axonal loss is not one disease but a common downstream outcome of many diseases and injuries. The pathways that cause it overlap, but the starting points are distinct.
Multiple Sclerosis
In MS, the immune system attacks the myelin insulation around axons in the brain and spinal cord. For a long time the focus was on demyelination, but research has shown that axonal damage is also a consistent and early feature. A landmark study examining MS lesion tissue found that the number of transected axons was directly related to how inflamed the lesion was: active lesions averaged over 11,000 cut axons per cubic millimeter of tissue, while the quieter centers of chronic lesions had far fewer.7PubMed. Axonal transection in the lesions of multiple sclerosis Some of this damage results from long-term demyelination and the energy crisis described above, but some appears to be independent of myelin loss altogether, driven by direct immune attack or other mechanisms.8PubMed Central. Axonal damage in multiple sclerosis
ALS and the Dying-Back Pattern
Amyotrophic lateral sclerosis is often described as a disease of motor neurons, the nerve cells in the brain and spinal cord that control voluntary movement. But the damage does not begin at the cell body. Instead, the far ends of the axons, at the junctions where nerves meet muscles, deteriorate first. The cell bodies in the spinal cord can remain intact long after their distant axon terminals have already pulled away from muscle fibers.9PubMed. The “dying-back” phenomenon of motor neurons in ALS Work in a widely studied mouse model of ALS showed this timeline in sharp detail: roughly 40 percent of muscle endplates were already denervated at a point when there was no evidence of cell-body loss. Motor neuron death itself did not become apparent until well after the distal axon damage was underway, and inflammatory changes around the cell bodies came even later.10PubMed. Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man This dying-back pattern has pushed researchers to look for therapies that protect the axon tips, where the disease arguably begins, rather than focusing solely on keeping the cell body alive.
Diabetic Neuropathy
Diabetes is one of the most common causes of peripheral axonal loss worldwide. Chronically high blood sugar and insulin abnormalities set off a cascade of metabolic problems that damage axons over years. The neuropathy in type 1 diabetes, where the body produces little or no insulin, tends to produce more severe axon shrinkage and loss, while type 2 diabetes, which involves insulin resistance, more often shows milder axonal involvement mixed with damage to the myelin sheath.11PubMed. Mechanisms of diabetic neuropathy: axon dysfunction In advanced cases, the sensory loss can be extensive, affecting not just the hands and feet but creeping up to the trunk, and sometimes even the scalp. Neuropathic pain is common, and autonomic dysfunction, problems with blood pressure regulation, digestion, or sweating, occurs in the vast majority of those with advanced disease.12PubMed. Sensory loss, pains, motor deficit and axonal regeneration in length-dependent diabetic polyneuropathy
Chemotherapy-Induced Peripheral Neuropathy
Many cancer-fighting drugs damage peripheral nerves as a side effect. Despite acting through different mechanisms on cancer cells, these drugs share a tendency to disrupt axonal transport, the internal conveyor belt that moves essential cargo up and down the axon. The severity of the resulting neuropathy generally tracks with how badly a drug interferes with this transport system.13PubMed Central. Axonal Transport Impairment in Chemotherapy-Induced Peripheral Neuropathy Microtubule-targeting drugs are especially implicated: they disrupt the structural scaffolding that molecular motors use to carry vesicles along the axon, and lab studies have shown that different drugs in this class affect transport through distinct mechanisms and at different potencies.14PubMed Central. Effects of eribulin, vincristine, paclitaxel and ixabepilone on fast axonal transport and kinesin-1 driven microtubule gliding: implications for chemotherapy-induced peripheral neuropathy
Traumatic Brain Injury
The older view of traumatic axonal injury was that rapid acceleration and deceleration of the head physically tore axons apart at the moment of impact. That idea has been partially replaced. While some axons may indeed rupture immediately, the majority undergo a secondary process: the initial mechanical stretching triggers biochemical cascades including protein breakdown, DNA damage, and inflammatory signaling that lead to delayed axon severing over the hours and days that follow.15PubMed Central. Traumatic axonal injury (TAI): definitions, pathophysiology and imaging-a narrative review This distinction matters because it opens a treatment window: if most axonal death after a head injury is secondary rather than instantaneous, there is at least a theoretical opportunity to intervene before the damage is complete.
Other Causes
Disrupted axonal transport is a shared early feature across several neurodegenerative diseases beyond ALS, including Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, hereditary spastic paraplegia, and Charcot-Marie-Tooth disease.16PubMed Central. Disruption of axonal transport in neurodegeneration Toxic exposures also contribute: organophosphate pesticides can damage the nervous system through multiple pathways, including direct interactions with cholinesterase and other neural targets.17PubMed Central. Mechanisms of Neurotoxicity of Organophosphate Pesticides and Their Relation to Neurological Disorders Nutritional deficiencies can cause axonal damage as well. Vitamin B12 deficiency leads to a condition called subacute combined degeneration of the spinal cord, in which both the myelin sheath and the axons themselves are harmed. The same pattern can be triggered, sometimes more severely, by nitrous oxide abuse, which inactivates B12.18PubMed Central. Comparative study of subacute combined degeneration of the spinal cord due to nitrous oxide abuse and vitamin B12 deficiency
Symptoms and What They Depend On
Axonal loss does not produce a single set of symptoms. What you experience depends on whether sensory axons, motor axons, or autonomic axons are affected, and where along the nervous system the damage occurs. In peripheral neuropathies like those caused by diabetes or chemotherapy, the longest axons tend to fail first, so symptoms usually begin in the toes and feet and work their way upward. Numbness, tingling, burning pain, and loss of temperature sensation are typical early complaints. As more axons are lost, motor symptoms like weakness in the feet and hands can follow, along with autonomic problems such as abnormal sweating or drops in blood pressure when standing.
In central nervous system conditions like MS, the symptoms are more varied because the damage can occur almost anywhere in the brain or spinal cord. Loss of axons in the spinal cord’s motor tracts produces weakness or spasticity in the limbs. Damage to optic nerve axons reduces vision. Axonal loss in the brainstem can affect balance, swallowing, or eye movement. The progressive disability that accumulates in MS over years, the difficulty walking, the fatigue, the cognitive slowing, is driven substantially by axonal loss rather than by demyelination alone.
In ALS, because motor axons die back from the muscles first, early symptoms often include muscle twitching, cramping, and weakness in a hand or foot. By the time a person is diagnosed, a substantial fraction of the motor axons to the affected muscles may already be gone.
Diagnosing Axonal Loss
You cannot see axons degenerating from the outside, so clinicians rely on a combination of electrical tests, imaging, and blood or spinal fluid markers. Nerve conduction studies, which send small electrical pulses along peripheral nerves and measure the response, remain a workhorse. The amplitude of the response reflects how many axons are intact: a low amplitude indicates axonal loss, while a slowed conduction speed points more toward myelin damage. In practice, most neuropathies involve both, but the distinction helps guide diagnosis and prognosis.
Diffusion tensor imaging, an MRI technique that maps how water moves along nerve fibers, has become increasingly useful. In peripheral nerves, specific DTI measurements correlate with electrical markers of axon integrity and myelin health, providing structural detail that standard MRI cannot.19PLOS ONE. Peripheral Nerve Diffusion Tensor Imaging: Assessment of Axon and Myelin Sheath Integrity In animal models of optic nerve damage, DTI has been shown to detect axonal injury within hours of injury, earlier than conventional staining techniques could identify abnormalities.20PubMed Central. Diffusion tensor imaging detects retinal ganglion cell axon damage in the mouse model of optic nerve crush
Blood-based biomarkers are a fast-moving area. Neurofilament light chain, or NfL, is a structural protein that spills into the spinal fluid and blood when axons are damaged. It is elevated across a wide range of neurological disorders and can be measured from a simple blood draw, making it far more practical than a spinal tap.21PubMed Central. Neurofilament Light Chain as a Biomarker, and Correlation with Magnetic Resonance Imaging in Diagnosis of CNS-Related Disorders In traumatic brain injury, serum NfL levels have been shown to distinguish between mild and more severe injuries, to correlate with brain atrophy on MRI, and to remain elevated for years after injury, though they do gradually decline over time.22PubMed Central. Neurofilament light as a biomarker in traumatic brain injury NfL is not specific to any one disease, which limits its diagnostic usefulness, but it is valuable for tracking whether axonal damage is ongoing and whether a treatment is working.
Why the Brain Heals So Much Worse Than the Rest of the Body
One of the most frustrating facts in neurology is the gap in regenerative ability between the peripheral and central nervous systems. Peripheral nerves can regrow over long distances after injury, and many people recover meaningful function after a severed or crushed nerve. The central nervous system, the brain and spinal cord, is a different story: axon regeneration there is extremely limited, and injuries like spinal cord damage, stroke, and traumatic brain injury produce deficits that tend to be permanent.23PubMed Central. Axon Regeneration in the Peripheral and Central Nervous Systems
The difference is not entirely about the neurons themselves. The glial cells that surround axons behave very differently in the two systems. In peripheral nerves, Schwann cells actively support regrowth: they clear debris, form guide tubes, and secrete growth factors. In the brain and spinal cord, the equivalent cells and other glial populations produce molecules that actively inhibit axon extension, forming a kind of chemical barrier at the injury site.24PubMed. Contrasting the glial response to axon injury in the central and peripheral nervous systems Even within the CNS, though, there is some heterogeneity: certain neuron types retain more regenerative capacity than others, and neurons in lower vertebrates and younger animals can sometimes regrow central axons that adult mammals cannot.25PubMed Central. Heterogeneity in the regenerative abilities of central nervous system axons within species: why do some neurons regenerate better than others? Understanding what sets those neurons apart is one of the central goals of regeneration research.
Treatment Approaches and Emerging Therapies
No approved drug currently reverses axonal loss once it has occurred. The current treatment landscape is therefore divided into two strategies: managing the underlying disease to slow ongoing damage, and pursuing experimental therapies aimed at protecting axons before they are lost.
For disease-specific management, the approach depends on the cause. In MS, disease-modifying therapies that reduce immune attacks can slow the accumulation of axonal damage, though they do not repair axons that are already gone. In diabetic neuropathy, tight blood sugar control is the most effective way to limit further nerve damage. In chemotherapy-induced neuropathy, dose reduction or switching agents is often the only practical option, since no approved neuroprotective drug exists for this indication.
The most exciting experimental work centers on SARM1 inhibitors. As described earlier, SARM1 is the enzyme that executes axonal self-destruction when protective signals falter. Blocking SARM1 could, in theory, keep axons alive even when their support systems are compromised. In animal models of paclitaxel-induced neuropathy, an oral SARM1 inhibitor partially preserved nerve function: treated animals maintained better nerve signal amplitudes and retained more of the tiny sensory nerve fibers in the skin compared with untreated animals.26PubMed Central. Pharmacological SARM1 inhibition protects axon structure and function in paclitaxel-induced peripheral neuropathy Newer compounds targeting SARM1 are being characterized with an eye toward treating chemotherapy-induced neuropathy specifically, and early results suggest the approach has real potential as a neuroprotective strategy.27PubMed Central. Characterization of Novel SARM1 Inhibitors for the Treatment of Chemotherapy-Induced Peripheral Neuropathy These are still preclinical findings, and human trials will be needed to confirm whether the protection seen in rodents translates to patients, but SARM1 inhibition is the first mechanism-based approach that directly targets the axonal degeneration pathway rather than its upstream triggers.
For spinal cord injury, researchers have combined multiple strategies in animal experiments: peripheral nerve grafts to provide a physical scaffold for regrowing axons, enzymes to dissolve the growth-inhibiting molecules at the injury border, and exercise training to boost natural growth factors within the spinal cord.28PubMed Central. Axon regeneration and exercise-dependent plasticity after spinal cord injury The current consensus is that meaningful recovery after severe CNS injury will probably require combining several of these approaches rather than relying on any single one.
Axonal Loss With Normal Aging
You do not need a disease to lose axons. Normal aging is accompanied by a gradual, steady decline in myelinated nerve fibers in the brain. One study estimating total myelinated fiber length in the human brain found a loss of roughly 10 percent per decade, meaning that by age 80, about 45 percent of the myelinated fiber length present at age 20 had disappeared.29PubMed. Marked loss of myelinated nerve fibers in the human brain with age The same study found a sex difference: males had about 16 percent greater total fiber length than females at any given age, though both groups lost fibers at the same rate. This age-related loss likely contributes to the slowing of cognitive processing speed and the mild memory changes that are considered a normal part of aging, and it represents the baseline against which disease-related axonal loss is superimposed. It also helps explain why neurodegenerative diseases tend to become symptomatic in later life: an aging nervous system that has already lost a substantial fraction of its axonal reserves has less redundancy to mask additional losses from disease.
Recent work has tied this age-related decline to local energy problems in the axon itself, reinforcing the idea that bioenergetic failure is a shared mechanism underlying both normal aging and neurodegenerative disease.30PubMed Central. Axonal energy metabolism, and the effects in aging and neurodegenerative diseases Whether interventions that support axonal energy metabolism could slow age-related fiber loss is an open question, but it is one of the more compelling ideas in the prevention space right now.